24 citations
,
December 2011 in “International Journal of Cancer” PTH-CBD agonists may help regrow hair after chemotherapy.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
21 citations
,
April 2008 in “Toxicologic Pathology” CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.
26 citations
,
February 1998 in “Chemico-Biological Interactions” Scientists identified three genes important for processing certain brain chemicals, thyroid hormones, and medications.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
November 2005 in “CRC Press eBooks” SEPA 0009 is a promising and safe skin penetration enhancer for topical use.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
38 citations
,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
1 citations
,
May 2023 in “Elsevier eBooks”
The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.
August 2025 in “MedScien” Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.
July 2023 in “International Journal of Molecular Sciences” Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.
125 citations
,
May 2019 in “Phytomedicine” Cepharanthine is a well-tolerated drug with multiple medical uses, including anti-inflammatory and anti-cancer properties.
73 citations
,
October 2003 in “Journal of Pharmacology and Experimental Therapeutics” Hair color loss can indicate the effectiveness of a drug targeting the KIT protein in mice and humans.
58 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Pioglitazone may help treat lichen planopilaris, but more research is needed.
9 citations
,
October 2015 in “Journal of Cutaneous Pathology” Erythematous papulopustular eruptions in cancer patients using EGFR inhibitors show specific skin changes that vary with severity and treatment type.
December 2004 in “Annales d Urologie” Finasteride may reduce prostate cancer risk.
Androgen-modulating drugs do not significantly change the heat sensitivity of prostate cancer cells.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
January 1989 in “Side effects of drugs annual” Some cancer and immune system drugs can cause serious side effects, including heart, lung, nerve, and organ damage, which need careful monitoring and management.
July 2024 in “Journal of Investigative Dermatology” PP405 may help hair growth by activating hair follicle stem cells.
1 citations
,
April 2009 in “Journal of Intellectual Property Law & Practice” UK courts and the European Patent Office are now more open to granting patents for new dosage regimes.
February 2006 in “Inpharma Weekly”
45 citations
,
January 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
29 citations
,
October 2016 in “Cell death and differentiation” ΔNp63α stops TAp73β from working in skin cancer by blocking its access to specific genes, not by directly interacting with it.
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
May 2023 in “Journal of Investigative Dermatology” Blocking DPP4 can potentially speed up hair growth and regeneration, especially after injury or in cases of hair loss.
11 citations
,
June 2016 in “European Journal of Medicinal Chemistry” Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.
September 2019 in “Journal of Investigative Dermatology” PCE-DP brightens skin and promotes hair growth by enhancing cell growth and reducing melanin uptake.